Larvol Delta - ADC-Therapeutics-Announces-Encouraging-Interim-Results-from-Pivotal-Phase-2-Clinical-Trial-of-Camidanlumab-Tesirine-Cami-Presented-at-the-16th-Annual-International-Conference-on-Malignant-Lymphoma

camidanlumab tesirine (ADCT-301) - Genmab, ADC Therapeutics

https://www.businesswire.com/news/home/20210622005355/en/ADC-Therapeutics-Announces-Encouraging-Interim-Results-from-Pivotal-Phase-2-Clinical-Trial-of-Camidanlumab-Tesirine-Cami-Presented-at-the-16th-Annual-International-Conference-on-Malignant-Lymphoma

Jun 22, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next